NasdaqCM - Delayed Quote USD

NexImmune, Inc. (NEXI)

3.3700

-0.0400

(-1.17%)

At close: April 26 at 4:00 PM EDT

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (

GlobeNewswire 2 months ago

NEXI
-1.17%
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or c

GlobeNewswire 2 months ago

NEXI
-1.17%
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It’s the final day of trading this week and we’re starting it with a breakdown of the biggest pre-market stock movers on Friday morning! Moving stocks this morning are updates from the U.S. Food and Drug Administration (FDA), public share offerings and more. Let’s get into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Green Giant (NASDAQ:GGE) stock is rocketing more than 108% after revealing details of its 2023 Equi

InvestorPlace 4 months ago

BIOR

GGE

NEXI
-1.17%
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

GlobeNewswire 5 months ago

NEXI
-1.17%
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.

GlobeNewswire 6 months ago

NEXI
-1.17%
NexImmune Announces 1-for-25 Reverse Stock Split

GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Com

GlobeNewswire 6 months ago

NEXI
-1.17%
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that, in order to re

GlobeNewswire 7 months ago

NEXI
-1.17%
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments; one patient continues to show no evidence of disease at nine months Preclinical data demonstrates superior potency and durability when combining T cell engager (TCE) bispecific agents with AIM-expanded multi-tumor-antigen-specific T cell at low doses NIH collaboration demonstrate

GlobeNewswire 8 months ago

NEXI
-1.17%
$NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting$
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023 - Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Antigen-specific T cells persist in blood and bone marrow and maintain important phenotypes that are

GlobeNewswire 10 months ago

NEXI
-1.17%
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease Data suggests a potential therapeutic role for AIM multi-antigen-specific products in multiple sclerosis GAITHERSBURG, Md., May 22, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune

GlobeNewswire 10 months ago

NEXI
-1.17%
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the first

GlobeNewswire 11 months ago

NEXI
-1.17%

Performance Overview

Return	NEXI	S&P 500
YTD	+51.80%	+6.92%
1-Year	-65.96%	+25.26%
3-Year	-99.31%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NexImmune, Inc. (NEXI)

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Performance Overview